Curiox Biosystems Co., Ltd.
KKRX:44568060,000.00
KRW
0.00
(0.00%)
ISIN
KR7445680002
Return %
Stock
S&P 500
1Y
-16.78
14.20
3Y
277.36
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Nam-Yong Kim
- Full Time Employees
- 22
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Seoul South Korea
- IPO Date
- Aug 10, 2023
- Website
- curiox.co.kr
- Similar Companies
- Business
- Curiox Biosystems Co., Ltd. is a South Korea-based life sciences technology and instrumentation company that specializes in the development, manufacturing, and commercialization of automated, non-centrifugal sample preparation systems for cell analysis and biological research. Founded in 2008 and headquartered in Seongnam-si, South Korea, the company operates globally through its primary United States subsidiary, Curiox Biosystems, Inc., located in Woburn, Massachusetts, alongside regional business operations and distribution networks spanning North America, Europe, and the Asia-Pacific region. Curiox Biosystems provides proprietary cell preparation technologies designed to replace conventional centrifugation methods, thereby preserving cell viability, standardizing biological assays, and eliminating manual handling variability in flow cytometry, single-cell genomics, proteomics, and cell and gene therapy applications. The company categorizes its commercial offerings into automated instrumentation systems; proprietary consumables and surface-treated microplates; and technical validation and support services. Its core product portfolio comprises automated cell washing instruments based on its proprietary Laminar Wash technology, including the Laminar Wash AUTO1000 and AUTO2000 fully automated cell washing systems for high-throughput screening; the Laminar Wash HT2000 multi-well system engineered for high-content analysis and genomics; the Laminar Wash MINI1000 benchtop system designed for low-to-medium throughput laboratory workflows; the Curiox Pluto and Pluto LT automated sample preparation workstations; and robotic automation integration modules compatible with third-party liquid handling systems. In addition to hardware, the company manufactures and sells specialized consumables, including proprietary 96-well and 384-well Laminar Wash drop-array microplates, buffer reagents, cleaning solutions, and maintenance kits, while providing assay development, protocol optimization, and equipment validation services to biopharmaceutical companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and academic research institutes. In recent corporate and operational developments, Curiox Biosystems completed its initial public offering on the KOSDAQ market of the Korea Exchange (Ticker: 445680), accelerating the international commercialization of its Laminar Wash platform. The company has actively expanded strategic alliances and commercial partnerships with global life science automation and flow cytometry providers, including collaborative integration initiatives with Beckman Coulter Life Sciences and standard-setting participation in the National Institute of Standards and Technology (NIST) flow cytometry consortia to establish automated cell washing as a benchmark in cell therapy manufacturing and characterization. Furthermore, Curiox Biosystems has broadened its product pipeline with next-generation automated sample preparation platforms tailored for single-cell sequencing and clinical-grade cell therapy quality control, while expanding its global direct sales infrastructure and distributor networks across the United States, Europe, and Asian markets.